Breaking News

SAB Receives $35.6 Miliion from U.S. DOD

Funds rapid response antibody program to combat COVID-19.

By: Contract Pharma

Contract Pharma Staff

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human donors, has been awarded an additional $35.6 million in expanded scope for its DiversitAb Rapid Response Antibody Program contract from the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO – CBRND) Joint Project Lead for Chemical, Biological, Radi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters